Scottish children with multiple neurodevelopmental conditions experience greater school absenteeism and exclusion, poorer exam attainment and increased unemployment, according to a study published October 13 in the open-access journal PLOS Medicine by Michael Fleming of the University of Glasgow, and colleagues.
Children with neurodevelopmental conditions such as attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), depression and intellectual disability often experience difficulties at school. Multiple neurodevelopmental conditions commonly coexist, but this phenomenon, known as neurodevelopmental multimorbidity, has received relatively little attention in children compared to adults. To address this gap in knowledge, Fleming and his collaborators investigated the prevalence of neurodevelopmental multimorbidity in Scottish schoolchildren and their educational outcomes compared to their peers. The authors linked together five Scotland-wide health and education databases to identify neurodevelopmental multimorbidity in 766,244, four- to 19-year-old children attending school in Scotland between 2009 and 2013. Study limitations are that 96.2% of the participants
Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy, report University of California San Diego School of Medicine researchers.
Led by Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at Moores Cancer Center and senior author of the study, a multidisciplinary molecular tumor board was established to advise treating physicians on course of care using an individual patient’s molecular tumor makeup to design precision medicine strategies.
“Patients who underwent a molecular tumor board-recommended therapy were better matched to genomic alterations in their cancer and had improved outcomes,” said Kurzrock. “The three-year survival for patients with the highest degree of matching and who received a personalized cancer therapy was approximately 55 percent compared to 25 percent in patients who received therapy that
This month’s cache of Insights & Outcomes includes a map of the human retina, a menu of African savanna diets, and a much-deserved honor for a Yale chemist.
As always, you can find more science and medicine research news on YaleNews’ Science & Technology and Health & Medicine pages.
John C. Tully wins Zewail Prize in Molecular Sciences
John C. Tully, Sterling Emeritus Professor of Chemistry and professor of physics and applied physics, is the winner of the 8th Ahmed Zewail Prize in Molecular Sciences. The prize, developed by the international journal Chemical Physical Letters and the scientific information publisher Elsevier, is awarded biennially to a scientist who has made “significant and creative contributions, particularly those of a fundamental nature, to any of the disciplines of molecular sciences.” Prize officials said Tully was chosen for his “development and insightful application of powerful theoretical tools to elucidate the motions of
Marketers have been chasing lower CPM (cost per thousand) prices, particularly in programmatic channels, thinking that leads to greater “efficiency” in their digital ad spending. That is wrong and it’s just a race to the bottomless pit of ad fraud and adtech middlemen taking a greater and greater share of every dollar spent by the marketer.
Real, mainstream publishers with real reporters and editors create real content for real human audiences. They cannot afford to sell ad impressions at very low prices. But fake sites and app publishers can afford to sell ads at very low CPMs because they have no cost of content and low operating costs — think piracy sites, bot generated sites, etc. Those bot generated sites have no human audiences because they don’t need humans. They just use bot traffic to create billions of impressions to sell through programmatic exchanges to unsuspecting advertisers.
It saved lives in past epidemics of lung-damaging viruses. Now, the life-support option known as ECMO appears to be doing the same for many of the critically ill COVID-19 patients who receive it, according to a new international study.
The 1,035 patients in the study faced a staggeringly high risk of death, as ventilators and other care failed to support their lungs. But after they were placed on ECMO, their actual death rate was less than 40%. That’s similar to the rate for patients treated with ECMO in past outbreaks of lung-damaging viruses, and other severe forms of viral pneumonia.
The new study published in The Lancet provides strong support for the use of ECMO — short for extracorporeal membrane oxygenation — in appropriate patients as the pandemic rages on worldwide.
It may help more hospitals that have ECMO capability understand which of their COVID-19 patients might benefit from the